Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525691 | 1.00 | MEN1 (0.36) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL550601 | 0.77 | IDO1 (0.39) | MEN1LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL6731218 | 0.66 | MEN1 (0.46) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL30086144 | 0.66 | LMNA (0.55) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL3612898 | 0.66 | LMNA (0.55) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL15236205 | 0.66 | IDO1 (0.36) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL976750 | 0.64 | LMNA (0.52) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL4951213 | 0.64 | KMT2A (0.65) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL4137855 | 0.64 | CYP1A2 (0.31) | — | |
| SCHEMBL10689272 | 0.63 | IDO1 (0.34) | MEN1LMNAKMT2ATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022094174-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| EP-4482511-A2 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | The Regents of The University of Michigan (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023164476-A2 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-31 | — | — | WO | disclosed |
| CN-107510694-B | Compound for activating latent infected AIDS virus and application thereof in AIDS treatment | 中国科学院上海巴斯德研究所 | 2022-03-29 | — | — | CN | disclosed |
| US-10751322-B2 | Indole-3-aldehyde for treating dysreactive immune disorders | Universita′ degli Studi di Perugia (IT) | 2020-08-25 | — | — | US | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20160206595-A1 | INDOLE-3-ALDEHYDE FOR TREATING DYSREACTIVE IMMUNE DISORDERS | UNIVERSITA' DEGLI STUDI DI PERUGIA (IT) | 2016-07-21 | — | — | US | disclosed |
| EP-3035967-A1 | INDOLE-3-ALDEHYDE FOR TREATING DYSREACTIVE IMMUNE DISORDERS | Universita Degli Studi Di Perugia (IT) | 2016-06-29 | — | — | EP | disclosed |
| US-20160074400-A1 | WNT MODULATORS FOR THE PROTECTION, MITIGATION AND TREATMENT OF RADIATION INJURY | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2016-03-17 | — | — | US | disclosed |
| WO-2015025259-A1 | INDOLE-3-ALDEHYDE FOR TREATING DYSREACTIVE IMMUNE DISORDERS | UNIVERSITA' DEGLI STUDI DI PERUGIA (IT) | 2015-02-26 | — | — | WO | disclosed |
| US-20140050694-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10751322-B2 | Indole-3-aldehyde for treating dysreactive immune disorders | IDO1, IDO2, KYNU | MEN1 3070/4885LMNA 4803/4885THRB 985/4885 |
| US-20160206595-A1 | INDOLE-3-ALDEHYDE FOR TREATING DYSREACTIVE IMMUNE DISORDERS | IDO1, IDO2, KYNU | MEN1 3133/4885LMNA 4810/4885THRB 900/4885 |
| US-20160074400-A1 | WNT MODULATORS FOR THE PROTECTION, MITIGATION AND TREATMENT OF RADIATION INJURY | WNT3A, IWS1, WNT1 | MEN1 4555/4885LMNA 1681/4885THRB 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.